Clostridium Difficile Infections Market
DelveInsight’s ‘Clostridium difficile Infection - Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Clostridium difficile Infection, historical and forecasted epidemiology as well as the Clostridium difficile Infection market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Clostridium difficile Infection market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted the 7MM Clostridium difficile Infection market size from 2019 to 2032. The Report also covers current Clostridium difficile Infection treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Clostridium difficile Infection Understanding and Treatment Algorithm
Clostridium difficile Infection Overview
Clostridium difficile Infection (CDI) is a common nosocomial and community-acquired infection, caused by gram-positive, anaerobic, spore-forming Clostridium difficile bacteria. It is responsible for about half a million infections in the US yearly. A highly contagious and recurrent disease, it is usually associated with diarrhea and colitis.
The global incidence of the disease is increasing making it a major public health challenge. Old age, antibiotic exposure, weak immune system, and other illnesses disrupt the microbiota, generating an environment conducive to Clostridium difficile spore germination and vegetative cell outgrowth leading to bacterial overgrowth. Usually found in unhygienic conditions, the bacteria are transmitted via the fecal-oral route, hand-to-hand contact, and airborne environmental dispersal in hospitals.
The Clostridium difficile bacteria is a toxin-producing pathogen that produces two types of toxins: toxin A (an enterotoxin) and toxin B (a cytotoxin). This toxin-producing ability is the reason that Clostridium difficile can produce a range of disease severities Clostridium difficile Infection, from mild to moderate and severe to even fatal
The clinical symptoms of Clostridium difficile Infection are heterogeneous and range from very mild diarrhea to fulminant colitis, accompanied by complications such as toxic megacolon, bowel perforation, sepsis, and death. Extracolonic manifestations of Clostridium difficile Infection are rare and most commonly involve small intestine infiltration, reactive arthritis, and bacteremia.
Due to the fastidious nature of Clostridium difficile, the isolation and characterization of this pathogen were challenging for routine microbiology laboratories. But in the last two decades, with advances in molecular biology techniques, there have been breakthroughs in our understanding of the genetic diversity, evolution, epidemiology, and pathogenicity of Clostridium difficile.
Clostridium difficile Infection Diagnosis
Diagnostic testing for Clostridium difficile Infection should be performed only in symptomatic patients. Laboratory diagnosis of Clostridium difficile Infection requires demonstration of Clostridium difficile toxin or detection of toxigenic Clostridium difficile organisms. For patients with ileus and suspected Clostridium difficile Infection, laboratory diagnosis via rectal swab for toxin assay or anaerobic culture may be performed. The sensitivity of rectal swabs for Clostridium difficile culture in the setting of ileus is high
The definitive gold standard for Clostridium difficile Infection, is the detection of toxigenic Clostridium difficile bacteria, in the stool and colonic histopathology. Stool tests most commonly used are diagnosis are GDH, Toxin EIA, and Toxin B PCR. It is recommended that a two-step algorithm be used to confirm the diagnosis of Clostridium difficile, where GDH or Toxin B PCR are used as screening tests, and the Toxin EIA is used to confirm the diagnosis.
More recently, molecular tests like NAAT, which are fast and more sensitive, has to lead to improved Clostridium difficile Infection diagnosis. The use of NAATs is preferred for laboratory diagnosis of Clostridium difficile, either alone or as part of an algorithm including initial EIA screening for glutamate dehydrogenase (GDH) antigen and toxins A and B.
Continued in the report…..
Clostridium difficile Infection Treatment
The current treatment regime for Clostridium difficile is therapeutic and not prophylactic. Treatment is restrictive and challenging due to the high recurrence rates, with most broad-spectrum antibiotics like clindamycin, cephalosporins, quinolones, and penicillins increasing the risk of Clostridium difficile Infection for they deplete gut microbiota, providing an environment conducive for Clostridium difficile multiplication.
The current recommended period of antimicrobial therapy for primary Clostridium difficile Infection is 10–14 days, but there is a significant therapeutic conundrum because restoration of gut microbiota diversity is necessary for recovery; that gets disrupted due to extended antibiotic use.
Most treatment guidelines recommend vancomycin, fidaxomicin, and metronidazole as the antibiotics of choice for various lines of therapy. Though metronidazole is an easily available drug, its pharmacokinetics for intestinal infections are inconsistent, thereby making vancomycin or fidaxomicin preferred options for all clinically significant cases of Clostridium difficile Infection.
Oral vancomycin is typically well-tolerated and the most prescribed drug of choice for treating Clostridium difficile Infection and associated conditions. However, the recently updated guidelines (both IDSA-SHEA guidelines and ESCMID), recommend fidaxomicin for 10 days as the preferred treatment for initial and recurrent Clostridium difficile Infection, due to its narrow spectrum of action and antimicrobial stewardship. In 2011, the US FDA approved Merck’s DIFICID (fidaxomicin) for the treatment of CDAD in adults, and in 2020 approved its use for the treatment of Clostridium difficile Infection in children aged six months or older also.
However, with high rates of recurrence, conventional antibiotic has limitations. In such scenarios, with limited therapeutic options managing patients with rCDI is a major clinical challenge. Pulsed tapered vancomycin is the usual treatment for rCDI, and combination therapies or fidaxomicin are also recommended.
The US FDA also approved ZINPLAVA (bezlotoxumab) to prevent rCDI in adults at high risk for recurrence. It binds to Clostridium difficile toxin B, neutralizes its effect, and is recommended as an adjunct therapy to improve the gut microbiota, the prima facie goal for any Clostridium difficile Infection treatment.
However, with increasing antibiotic resistance rates in the last decade, the efficacy of the currently endorsed treatments has reduced. Thus there is a need for palliative and more C.difficile-specific treatment.
Continued in the report…..
Clostridium difficile Infection Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Clostridium difficile Infection, Gender-specific Incident Cases of Clostridium difficile Infection, Type-specific Incident Cases of Clostridium difficile Infection, Age-specific Incident Cases of Clostridium difficile Infection, and Severity-specific Incident Cases of Clostridium difficile Infection scenario of Clostridium difficile Infection in the 7MM covering the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
- According to DelveInsight estimates, the total incident cases of Clostridium difficile Infection in the 7MM were found to be approximately 668,729 cases in 2021. These cases are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019 ─2032).
- Among the 7MM, the United States accounted for the highest incidence of Clostridium difficile Infection with nearly 70.1% of the total incident cases of Clostridium difficile Infection in the 7MM, followed by EU-5, in the year 2021, which is expected to increase further by 2032.
- As per DelveInsight analysis, in EU-5, there were approximately 100,004 hospital-acquired Clostridium difficile Infection (HA-CDI) cases and approximately 37,966 community-acquired Clostridium difficile Infection (CA-CDI) cases in 2021, which are expected to increase by 2032.
- According to estimates based on DelveInsight’s epidemiology model, for age-specific infection cases, the ≥65 age group makes up the majority of the Clostridium difficile Infection cases, followed by the 18–64 age group, while the least cases are in the <18 age-group.
- According to estimates based on DelveInsight’s epidemiology model for Clostridium difficile Infection, the severity-specific Clostridium difficile Infection cases in Japan were found to be approximately 44,754 mild to moderate cases and approximately 13,974 severe cases in 2021, which are expected to decrease by 2032.
Country-Wise Clostridium difficile Infection Epidemiology
The epidemiology segment also provides the Clostridium difficile Infection epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Clostridium difficile Infection Drug Chapters
The drug chapter segment of the Clostridium difficile Infection report encloses a detailed analysis of Clostridium difficile Infection marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Clostridium difficile Infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Clostridium difficile Infection Emerging Drugs
The emerging pipeline for CDI is robust. The potential emerging treatment expected to launch in the forecast period includes both preventive and therapeutic agents.
PF-06425090 (C. difficile vaccine): Pfizer
PF-06425090 (C. difficile vaccine) by Pfizer is a prophylactic vaccine being developed to prevent primary CDI (P-CDI) in adults aged 50 and older. It is a bivalent toxoid vaccine that preserves important antigenic epitopes, as it is a genetically detoxified toxin. In March 2022, Pfizer announced results from its pivotal Phase III CLOVER trial, evaluating the vaccine candidate, PF-06425090, for the prevention of CDI. Though the trial did not meet its prespecified primary endpoint of prevention of primary CDI, its safety reviews indicated that the investigational vaccine was safe and well tolerated. Pfizer is currently evaluating the next steps for the program in coordination with regulatory agencies. PF-06425090 received FTD (Fast Track designation) from the US FDA.
Products detail in the report…
CP101: Finch Therapeutics
CP101, being developed by Finch Therapeutics, is an investigational, orally administered microbiome drug for conditions linked to microbiome dysfunction. CP101 delivers complete microbiome communities in orally administered, enteric-release capsules. CP101 is in late-stage clinical development for the prevention of rCDI. The company is planning to deploy CP101 to other conditions linked to microbiome disruption, starting with the evaluation of CP101 as a treatment for chronic hepatitis B. Recently, the US FDA has removed the clinical hold on Finch’s investigational new drug (IND) application for CP101. The drug received FTD and BTD (Breakthrough Designation) from the US FDA to treat rCDI. The company has initiated patient dosing in the PRISM4 (Phase III) trial of CP101 for the prevention of rCDI and anticipates topline data in H1 2024.
Products detail in the report…
VE303: Vedanta Biosciences
VE303, being developed by Vedanta Biosciences, is an orally administered bacterial consortium candidate for high-risk CDI. VE303 consists of eight types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile. VE303 is produced from clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing from the donor’s fecal material of the inconsistent composition. It is designed to induce immune tolerance in the gut, reverse the gut microbiota abnormalities common in patients with IBD, and strengthen the epithelial barrier. In October 2021, in a Phase II trial of patients at high risk of recurrence, VE303 met its primary endpoint of preventing CDI recurrence at 8 weeks, and the company is planning to initiate a Phase III trial in 2022. The US FDA granted ODD (Orphan Drug Designation) to VE303 for treating rCDI.
Products detail in the report
NTCD-M3: Destiny Pharma
NTCD-M3 (a non-toxigenic strain of C. difficile bacteria- strain M3), previously known as VP-20621, is being developed by Destiny Pharma for the treatment of recurrent CDI. It is an oral formulation of NTCD-M3 spores. NTCD-M3 temporarily colonizes the human gut without causing any symptoms and the gut microbiome returns to normal a few weeks after treatment. Therefore, it acts as a safe ground cover and prevents the toxic strains of C. difficile from proliferating in the colon after antibiotic treatment. NTCD-M3 has completed a randomized, double-blind, placebo-controlled Phase IIb clinical study and reported strong, statistically significant data confirming efficacy.
Destiny Pharma plans to start the Phase III trial by mid of 2023, the design for which was approved by the US FDA in July 2020. It is conducting partnership discussions to co-fund the planned Phase III clinical studies and the subsequent commercialization. It has also received positive scientific advice from EMA on the proposed Phase III study design. The US FDA granted FTD to NTCD-M3 for the treatment of rCDI.
Products detail in the report.
REBYOTA (RBX2660): Ferring Pharmaceuticals
REBYOTA (RBX2660), being developed by Ferring Pharmaceuticals, is a first-in-class microbiota-based live biotherapeutic product to deliver a broad consortium of diverse microbes to the gut to reduce rCDI. It is administered directly into the patient’s intestine through the rectum as an enema. Recently, Ferring Pharmaceuticals reported successful results from the Phase III PUNCH CD3 clinical trial demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing the recurrence of CDI over placebo. The company has leveraged its clinical, manufacturing, and regulatory experience with RBX2660 to develop a lyophilized non-frozen oral capsule formulation RBX7455. Ferring plans on conducting a Phase III study of RBX7455, that enhances the clinical pipeline of human microbiome-directed drug candidates. In September 2022, the VRBPAC of the US FDA reviewed the data supporting the BLA for RBX2660 and issued a positive vote for REBYOTA (RBX2660). The US FDA has granted FTD, BTD, and ODD to REBYOTA (RBX2660) for treating rCDI.
Products detail in the report
SER-109: Seres therapeutics
SER-109 being developed by Seres therapeutics is a potential first-in-class investigational oral microbiome therapeutic designed to reduce the recurrence of CDI in patients with rCDI. It is a multifunctional consortium of commensal bacteria based on human clinical insights and is to be administered orally following antibiotics. Seres Therapeutics has completed multiple Phase III trials for SER-109 and had filed for BLA submission that was accepted for Priority Review. It anticipates the potential approval and launch of SER-109 by the first half of 2023, with SER-109 potentially becoming the first-ever FDA-approved oral microbiome therapeutic. The drug has been granted BTD and ODD designations by FDA for rCDI treatment.
Products detail in the report…
Ridinilazole: Summit Therapeutics
Ridinilazole, being developed by Summit Therapeutics, is an investigational bisbenzimidazole oral antimicrobial that targets C. difficile whilst sparing the gut microbiome and producing protective secondary bile acids; it is highly specific and bactericidal against C. difficile. The Phase III trials were pivotal trials comparing ridinilazole to vancomycin and designed to show superiority over one of the current standard-of-care antibiotics, vancomycin. In the clinical trials, ridinilazole failed to show superiority over vancomycin. The company is advised to conduct additional Phase III trials to achieve the primary endpoints. In October 2022, Summit Therapeutics shared the results from its Ri-CoDIFy Phase III clinical trial through an oral abstract presentation at IDWeek 2022, however, the statement provided no update on its plans for ridinilazole.
Products detail in the report…
MGB-BP-3: MGB Biopharma
MGB-BP-3, being developed by MGB Biopharma, is a potent bactericidal antibiotic that is an oral formulation with a novel mode of action for the treatment of Clostridium difficile-associated disease (CDAD). MGB-BP-3 has a fast bactericidal effect which can kill C. difficile in its vegetative form before it forms spores, thus achieving an initial cure and preventing the disease from recurring by reducing the total burden of C. difficile. Moreover, MGB-BP-3 has strong bactericidal activity against the BI/NAP1/027 strain, the most virulent strain that is largely resistant to current therapy. In January 2021, MGB Biopharma completed its End-of-Phase II (EOP2) meeting with the US FDA. The positive Phase II data showed that MGB-BP-3 provides high rates of sustained cure from CDI.
Products detail in the report…
List of products to be continued in the report…
Clostridium difficile Infection Market Outlook
Most treatment guidelines recommend vancomycin, fidaxomicin, and metronidazole as the antibiotics of choice for various lines of therapy. But since metronidazole's pharmacokinetics for intestinal infections are inconsistent, vancomycin or fidaxomicin are preferred options for all clinically significant cases of Clostridium difficile Infection. The current recommended period of antimicrobial therapy for primary Clostridium difficile Infection is 10–14 days, but there is a significant therapeutic conundrum because restoration of gut microbiota diversity is necessary for recovery; however, extended antibiotic use further disrupts intestinal flora.
As a result, probiotic therapy may be used after normal antibiotics to avoid recurrence and to restore microbiota, or low-dose antibiotics may be given intermittently to reduce the likelihood of recurrence. Bezlotoxumab, an antitoxin antibody, was recently approved by the US FDA to prevent rCDI in adults at high risk for recurrence.
In case of recurrences, there is a need to stop non-CDI antibiotics and take tapered or intermittent doses of anti-CDI antibiotics. Metronidazole is not recommended in case of the first recurrence, but vancomycin and fidaxomicin remain the antibiotic of choice in first or subsequent recurrence as the reason for recurrence is not the development of antimicrobial resistance by the infecting strain of Clostridium difficile. In some cases, along with standard treatment in recurrent Clostridium difficile Infection, a second anti-CDI antimicrobial agent (rifaximin) is also given as a chaser treatment. In case of multiple recurrences where anti-CDI antibiotics are not helpful, FMT is the best approach.
According to the updated IDSA-SHEA guidelines for managing CDI (2021), fidaxomicin for 10 days is the preferred treatment for initial and recurrent Clostridium difficile Infection. Oral vancomycin for 10 days at a standard dosing regimen is an acceptable alternative, while in nonsevere cases, metronidazole can be administered if the others are unavailable.
With growing antibiotic resistance, the cornerstones of Clostridium difficile Infection treatment changed from metronidazole or vancomycin to vancomycin or fidaxomicin. Since fidaxomicin reduced the rate of rCDI to about 15–20%, even in individuals with a history of rCDI, it became the drug of choice. It is a narrow-spectrum antibiotic with little systemic absorption.
Vancomycin in a tapered and pulsed regimen or vancomycin as a standard course is also an effective alternative in patients with a first recurrence. Furthermore, vancomycin, followed by rifaximin, and fecal microbiota transplantation are other alternatives to fidaxomicin for individuals with multiple recurrences.
These updated guidelines also recommend bezlotoxumab as an adjunct therapy for high-risk patients receiving antibiotic therapy. However, it carries a warning primarily in patients with a history of congestive heart failure (CHF), and its use is also limited by logistical factors such as insurance coverage, particularly in patients with the first episode of Clostridium difficile Infection.
The high rates of infection recurrences and depletion of the gut microbiota remain the main challenge in the clinical management of patients with Clostridium difficile Infection. Newer treatments that target the microbiome and are microbiome-sparing are needed. Considerable progress has been made in developing new anti-CDI drug candidates making the emerging pipeline for Clostridium difficile robust with multiple products in the late stages of development. Vaccines, microbiome therapy, and novel antibiotics are being developed to address the unmet need in Clostridium difficile Infection treatment.
The pipeline for CDI is dynamic, consisting of various agents such as PF-06425090 (Pfizer’s vaccine), CP101 (Finch Therapeutics), VE303 (Vedanta Biosciences), and NTCD-M3 (Destiny Pharma), REBYOTA (RBX2660) (Ferring Pharmaceuticals), SER-109 (Seres Therapeutics/ Nestle, Ridinilazole (Summit Therapeutics), and MGB-BP-3 (MGB Biopharma) which are expected to be launched during the forecast period (2022–2032). The launch of these is expected to address this unmet need and increase the market size in the coming years, assisted by an increase in the incident population of Clostridium difficile Infection during the forecast period.
According to DelveInsight, the overall dynamics of the Clostridium difficile Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies.
Key Findings
- The market size of the Clostridium difficile Infection in the seven major markets was approximately USD 413.5 million in 2021, which is further expected to increase by 2032.
- The United States accounts for the largest market size for Clostridium difficile Infection, in comparison to EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
- Among EU5 countries, Germany had the highest market size with approximately USD 19.5 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market followed by France in 2032.
- The market size for Clostridium difficile Infection in Japan was valued at approximately USD 35.6 million in 2021, which was approximately 8.61% of the total market of CDI. It is expected that the market will increase mainly due to the launch of upcoming therapy during the forecast period (2022–2032).
- The only vaccine anticipated to enter is Pfizer’s PF-06425090, which is expected to enter in 2025. With a medium fast uptake, and treatment modifying ability for individuals at risk for CDI or rCDI, it is projected to attain its peak in 6 years and by 2032 to approximately capture 15% of the total CDI market.
The United States Market Outlook
This section provides the total Clostridium difficile Infection market size and market size by therapies in the United States.
The EU-5 Market Outlook
The total Clostridium difficile Infection market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Clostridium difficile Infection market size and market size by therapies in Japan are provided.
Clostridium difficile Infection Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Clostridium difficile Infection market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Clostridium difficile Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allow, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Clostridium difficile Infection Development Activities
The report provides insights into different therapeutic candidates in the phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Clostridium difficile Infection emerging therapies.
Reimbursement Scenario in Clostridium difficile Infection
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Clostridium difficile Infection market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers a descriptive overview of Clostridium difficile Infection, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Clostridium difficile Infection epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Clostridium difficile Infection is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Clostridium difficile Infection market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Clostridium difficile Infection market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Clostridium difficile Infection market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Clostridium difficile Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Clostridium difficile Infection. The launch of emerging therapies will significantly impact the Clostridium difficile Infection market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Clostridium difficile Infection Report Insights
- Patient Population
- Therapeutic Approaches
- Clostridium difficile Infection Pipeline Analysis
- Clostridium difficile Infection Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Clostridium difficile Infection Report Key Strengths
- 11-Years Forecast
- The 7MM Coverage
- Clostridium difficile Infection Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Clostridium difficile Infection Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the Clostridium difficile Infection market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Clostridium difficile Infection total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Clostridium difficile Infection market size during the forecast period (2022–2032)?
- At what CAGR, the Clostridium difficile Infection market is expected to grow at the 7MM level during the forecast period (2022–2032)?
- What would be the Clostridium difficile Infection market outlook across the 7MM during the forecast period (2022–2032)?
- What would be the Clostridium difficile Infection market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of Clostridium difficile Infection?
- What is the historical Clostridium difficile Infection patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Clostridium difficile Infection at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Clostridium difficile Infection?
- Out of the above-mentioned countries, which country would have the highest incidence population of Clostridium difficile Infection during the forecast period (2022–2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Clostridium difficile Infection along with the approved therapy?
- What are the current treatment guidelines for the treatment of Clostridium difficile Infection in the US and Europe?
- What are the Clostridium difficile Infection marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Clostridium difficile Infection?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Clostridium difficile Infection?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Clostridium difficile Infection therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Clostridium difficile Infection and their status?
- What are the key designations that have been granted for the emerging therapies for Clostridium difficile Infection?
- What is the 7MM historical and forecasted market for Clostridium difficile Infection?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving Clostridium difficile Infection.
- To understand the future market competition in the Clostridium difficile Infection market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Clostridium difficile Infection in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- To understand the future market competition in the Clostridium difficile Infection market.
1. Key Insights
2. Report Introduction
3. CDI Market Overview at a Glance
3.1. Market Share (%) Distribution of CDI by Treatment in 2019
3.2. Market Share (%) Distribution of CDI by Treatment in 2032
4. CDI Market: Future Perspective
5. Executive Summary of CDI
6. Key Events
7. Disease Background and Overview of CDI
7.1. Introduction to CDI
7.2. Symptoms Associated with CDI
7.3. Causes
7.4. Risk Factors
7.5. Pathogenesis of CDI
7.5.1. Pathogenic factors
7.6. Clinical Manifestations
7.7. Infection Prevention and Control
7.8. Diagnosis
7.8.1. Diagnostic Algorithm
7.9. Treatment
7.9.1. Treatment Algorithm
7.10. Diagnosis and Treatment Guidelines
7.10.1. Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA)
7.10.2. American College of Gastroenterology (ACG)
7.10.3. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for C. difficile (ESGCD)
7.10.4. Japanese guidelines for the management of CDI
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: The 7MM
8.3.1. Incident Cases of CDI
8.3.2. Gender-specific Incident Cases of CDI
8.3.3. Type-specific Incident Cases of CDI
8.3.4. Age-specific Incident cases of CDI
8.3.5. Severity-specific Incident cases of CDI
8.3.6. Treated Cases of CDI
8.4. Total Incident Cases of CDI in the 7MM
8.5. The US
8.5.1. Total Incident Cases of CDI in the US
8.5.2. Gender-specific Incident Cases of CDI in the US
8.5.3. Type-specific Incident Cases of CDI in the US
8.5.4. Age-specific Incident Cases of CDI in the US
8.5.5. Severity-specific Incident Cases of CDI in the US
8.6. The Five European Countries
8.6.1. Total Incident Cases of CDI in the EU-5
8.6.2. Gender-specific Incident Cases of CDI in the EU-5
8.6.3. Type-specific Incident Cases of CDI in the EU-5
8.6.4. Age-specific Incident Cases of CDI in the EU-5
8.6.5. Severity-specific Incident Cases of CDI in the EU-5
8.6.6. Germany
8.6.6.1. Total Incident Cases of CDI in Germany
8.6.6.2. Gender-specific Incident Cases of CDI in Germany
8.6.6.3. Type-specific Incident Cases of CDI in Germany
8.6.6.4. Age-specific Incident Cases of CDI in Germany
8.6.6.5. Severity-specific Incident Cases of CDI in Germany
8.6.7. France
8.6.7.1. Total Incident Cases of CDI in France
8.6.7.2. Gender-specific Incident Cases of CDI in France
8.6.7.3. Type-specific Incident Cases of CDI in France
8.6.7.4. Age-specific Incident Cases of CDI in France
8.6.7.5. Severity-specific Incident Cases of CDI in France
8.6.8. Italy
8.6.8.1. Total Incident Cases of CDI in Italy
8.6.8.2. Gender-specific Incident Cases of CDI in Italy
8.6.8.3. Type-specific Incident Cases of CDI in Italy
8.6.8.4. Age-specific Incident Cases of CDI in Italy
8.6.8.5. Severity-specific Incident Cases of CDI in Italy
8.6.9. Spain
8.6.9.1. Total Incident Cases of CDI in Spain
8.6.9.2. Gender-specific Incident Cases of CDI in Spain
8.6.9.3. Type-specific Incident Cases of CDI in Spain
8.6.9.4. Age-specific Incident Cases of CDI in Spain
8.6.9.5. Severity-specific Incident Cases of CDI in Spain
8.6.10. The UK
8.6.10.1. Total Incident Cases of CDI in the UK
8.6.10.2. Gender-specific Incident Cases of CDI in the UK
8.6.10.3. Type-specific Incident Cases of CDI in the UK
8.6.10.4. Age-specific Incident Cases of CDI in the UK
8.6.10.5. Severity-specific Incident Cases of CDI in the UK
8.7 Japan
8.7.1 Total Incident Cases of CDI in Japan
8.7.2 Gender-specific Incident Cases of CDI in Japan
8.7.3 Type-specific Incident Cases of CDI in Japan
8.7.4 Age-specific Incident Cases of CDI in Japan
8.7.5 Severity-specific Incident Cases of CDI in Japan
9. Patient Journey
10. Marketed Therapies
10.1. Key Cross Competition
10.2. ZINPLAVA (bezlotoxumab): Merck & Co.
10.2.1. Product description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Clinical development
10.2.5. Clinical trials information
10.2.6. Safety and efficacy
10.2.7. Product profile
10.3. DIFICID/ DIFICLIR/ DAFCLIR (fidaxomicin): Merck & Co/ Tillotts Pharma/ Astellas Pharma
10.3.1. Product description
10.3.2. Regulatory milestones
10.3.3. Other development activities
10.3.4. Clinical development
10.3.5. Clinical trials information
10.3.6. Safety and efficacy
10.3.7. Product profile
11. Emerging Drugs
11.1. Key Cross Competition
11.2. Emerging Vaccines
11.2.1. PF-06425090: Pfizer
11.2.1.1. Product description
11.2.1.2. Other development activities
11.2.1.3. Clinical development
11.2.1.4. Clinical trials information
11.2.1.5. Safety and efficacy
11.2.1.6. Product profile
11.2.1.7. Analyst views
11.2.2. VLA84: Valneva
11.2.2.1. Product Description
11.2.2.2. Other Development Activities
11.2.2.3. Clinical Development
11.2.2.4. Clinical Trial Information
11.2.2.5. Safety and Efficacy
11.2.2.6. Product Profile
11.2.3. GSK2904545A: GlaxoSmithKline
11.2.3.1. Product description
11.2.3.2. Clinical development
11.2.3.3. Clinical trial information
11.2.3.4. Product profile
11.3. Emerging agents for Acute treatment of CDI
11.3.1. Ridinilazole: Summit Therapeutics
11.3.1.1. Product description
11.3.1.2. Other development activities
11.3.1.3. Clinical development
11.3.1.4. Clinical trial information
11.3.1.5. Safety and efficacy
11.3.1.6. Product profile
11.3.1.7. Analysts’ Views
11.3.2. MGB-BP-3: MGB Biopharma
11.3.2.1. Product description
11.3.2.2. Other development activities
11.3.2.3. Clinical development
11.3.2.4. Clinical trial information
11.3.2.5. Safety and efficacy
11.3.2.6. Product profile
11.3.2.7. Analysts’ views
11.3.3. Ibezapolstat: Acurx Pharmaceuticals
11.3.3.1. Product Description
11.3.3.2. Other Development Activities
11.3.3.3. Clinical Development
11.3.3.4. Clinical Trial Information
11.3.3.5. Safety and Efficacy
11.3.3.6. Product Profile
11.3.4. DAV132: Da Volterra
11.3.4.1. Product description
11.3.4.2. Other development activities
11.3.4.3. Clinical development
11.3.4.4. Clinical trial information
11.3.4.5. Safety and efficacy
11.3.4.6. Product profile
11.3.5. SYN-004 (ribaxamase): Synthetic Biologics
11.3.5.1. Product description
11.3.5.2. Other development activities
11.3.5.3. Clinical development
11.3.5.4. Clinical trial information
11.3.5.5. Safety and efficacy
11.3.5.6. Product profile
11.3.6. DNV3837: Deinove
11.3.6.1. Product description
11.3.6.2. Other development activities
11.3.6.3. Clinical development
11.3.6.4. Clinical trial information
11.3.6.5. Safety and efficacy
11.3.6.6. Product profile
11.3.7. OG716: Oragenics
11.3.7.1. Product description
11.3.7.2. Other development activities
11.3.7.3. Product profile
11.3.8. Research programme: C. difficile Monoclonal Antibody: XBiotech
11.3.8.1. Product description
11.3.8.2. Product profile
11.4. Emerging agents for Acute treatment of CDI and Prevention/Reduction of Recurrence
11.4.1. CRS3123: Crestone
11.4.1.1. Product description
11.4.1.2. Other development activities
11.4.1.3. Clinical development
11.4.1.4. Clinical trial information
11.4.1.5. Safety and efficacy
11.4.1.6. Product profile
11.4.2. OraCAb: MicroPharm Ltd.
11.4.2.1. Product description
11.4.2.2. Other development activities
11.4.2.3. Safety and efficacy
11.4.2.4. Product profile
11.4.3. SAB-195: SAb Biotherapeutics
11.4.3.1. Product description
11.4.3.2. Other development activities
11.4.3.3. Product profile
11.5. Emerging agents for Prevention/Reduction of recurrence
11.5.1. REBYOTA (RBX2660): Ferring Pharmaceuticals
11.5.1.1. Product description
11.5.1.2. Other development activities
11.5.1.3. Clinical development
11.5.1.4. Clinical trial information
11.5.1.5. Safety and efficacy
11.5.1.6. Product profile
11.5.1.7. Analysts’ views
11.5.2. SER-109: Seres Therapeutics/Nestlé Health Science
11.5.2.1. Product description
11.5.2.2. Other development activities
11.5.2.3. Clinical development
11.5.2.4. Clinical trials information
11.5.2.5. Safety and efficacy
11.5.2.6. Product profile
11.5.2.7. Analyst views
11.5.3. CP101: Finch Therapeutics
11.5.3.1. Product description
11.5.3.2. Other development activities
11.5.3.3. Clinical development
11.5.3.4. Clinical trial information
11.5.3.5. Safety and efficacy
11.5.3.6. Product profile
11.5.3.7. Analysts’ views
11.5.4. NTCD-M3: Destiny Pharma
11.5.4.1. Product Description
11.5.4.2. Other Development Activities
11.5.4.3. Clinical Development
11.5.4.4. Clinical Trial Information
11.5.4.5. Safety and Efficacy
11.5.4.6. Product Profile
11.5.4.7. Analysts’ Views
11.5.5. VE303: Vedanta Biosciences
11.5.5.1. Product description
11.5.5.2. Other development activities
11.5.5.3. Clinical development
11.5.5.4. Clinical trial information
11.5.5.5. Safety and efficacy
11.5.5.6. Product profile
11.5.5.7. Analysts’ views
11.5.6. MBK-01: Mikrobiomik Healthcare
11.5.6.1. Product description
11.5.6.2. Clinical development
11.5.6.3. Clinical trial information
11.5.6.4. Product profile
11.5.7. LMN-201: Lumen Bioscience
11.5.7.1. Product description
11.5.7.2. Other development activities
11.5.7.3. Clinical development
11.5.7.4. Clinical trial information
11.5.7.5. Safety and efficacy
11.5.7.6. Product profile
11.5.8. ADS024: Adiso Therapeutics
11.5.8.1. Product description
11.5.8.2. Other development activities
11.5.8.3. Clinical development
11.5.8.4. Clinical trial information
11.5.8.5. Product profile
11.5.9. REC-3964: Recursion Pharmaceuticals
11.5.9.1. Product description
11.5.9.2. Product profile
12. CDI: Market Analysis
12.1. Key Findings
12.2. Methodology of CDI Market
12.3. Key Market Forecast Assumptions
12.4. Market Outlook
12.5. Attribute Analysis
12.6. Market Size of CDI in the 7MM
12.7. Market Size of CDI by Therapies in the 7MM
12.8. Market Size of CDI in the US
12.8.1. Total Market Size of CDI
12.8.2. Market Size of CDI by Therapies
12.9. Market Size of CDI in the EU-5
12.9.1. Total Market Size of CDI
12.9.2. Market Size of CDI by Therapies
12.9.3. Germany
12.9.3.1. Total Market Size of CDI
12.9.3.2. Market Size of CDI by Therapies
12.9.4. France
12.9.4.1. Total Market Size of CDI
12.9.4.2. Market Size of CDI by Therapies
12.9.5. Italy
12.9.5.1. Total Market Size of CDI
12.9.5.2. Market Size of CDI by Therapies
12.9.6. Spain
12.9.6.1. Total Market Size of CDI
12.9.6.2. Market Size of CDI by Therapies
12.9.7. The UK
12.9.7.1. Total Market Size of CDI
12.9.7.2. Market Size of CDI by Therapies
12.10. Market Size of CDI in Japan
12.10.1. Total Market Size of CDI
12.10.2. Market Size of CDI by Therapies
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
16.1. The United States
16.1.1. Centre for Medicare and Medicaid Services (CMS)
16.2. The EU-5
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. The United Kingdom
16.3. Japan
16.3.1. MHLW
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Table
Table 1: Summary of CDI Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Diagnostic Tests for CDI
Table 4: Recommendation Statements of IDSA/SHEA Clinical Guideline for the Diagnosis of CDI
Table 5: ACG Guidelines for Diagnosis and Treatment of CDI
Table 6: Total Incident Cases of CDI in the 7MM (2019–2032)
Table 7: Total Incident Cases of CDI in the US (2019–2032)
Table 8: Gender-specific Incident Cases of CDI in the US (2019–2032)
Table 9: Type-specific Incident Cases of CDI in the US (2019–2032)
Table 10: Age-specific Incident Cases of CDI in the US (2019–2032)
Table 11: Severity-specific Incident Cases of CDI in the US (2019–2032)
Table 12: Total Incident Cases of CDI in the EU-5 (2019–2032)
Table 13: Gender-specific Incident Cases of CDI in the EU-5 (2019–2032)
Table 14: Type-specific Incident Cases of CDI in the EU-5 (2019–2032)
Table 15: Age-specific Incident Cases of CDI in the EU-5 (2019–2032)
Table 16: Severity-specific Incident Cases of CDI in the EU-5 (2019–2032)
Table 17: Total Incident Cases of CDI in Germany (2019–2032)
Table 18: Gender-specific Incident Cases of CDI in Germany (2019–2032)
Table 19: Type-specific Incident Cases of CDI in Germany (2019–2032)
Table 20: Age-specific Incident Cases of CDI in Germany (2019–2032)
Table 21: Severity-specific Incident Cases of CDI in Germany (2019–2032)
Table 22: Total Incident Cases of CDI in France (2019–2032)
Table 23: Gender-specific Incident Cases of CDI in France (2019–2032)
Table 24: Type-specific Incident Cases of CDI in France (2019–2032)
Table 25: Age-specific Incident Cases of CDI in France (2019–2032)
Table 26: Severity-specific Incident Cases of CDI in France (2019–2032)
Table 27: Total Incident Cases of CDI in Italy (2019–2032)
Table 28: Gender-specific Incident Cases of CDI in Italy (2019–2032)
Table 29: Type-specific Incident Cases of CDI in Italy (2019–2032)
Table 30: Age-specific Incident Cases of CDI in Italy (2019–2032)
Table 31: Severity-specific Incident Cases of CDI in Italy (2019–2032)
Table 32: Total Incident Cases of CDI in Spain (2019–2032)
Table 33: Gender-specific Incident Cases of CDI in Spain (2019–2032)
Table 34: Type-specific Incident Cases of CDI in Spain (2019–2032)
Table 35: Age-specific Incident Cases of CDI in Spain (2019–2032)
Table 36: Severity-specific Incident Cases of CDI in Spain (2019–2032)
Table 37: Total Incident Cases of CDI in the UK (2019–2032)
Table 38: Gender-specific Incident Cases of CDI in the UK (2019–2032)
Table 39: Type-specific Incident Cases of CDI in the UK (2019–2032)
Table 40: Age-specific Incident Cases of CDI in the UK (2019–2032)
Table 41: Severity-specific Incident Cases of CDI in the UK (2019–2032)
Table 42: Total Incident Cases of CDI in Japan (2019–2032)
Table 43: Gender-specific Incident Cases of CDI in Japan (2019–2032)
Table 44: Type-specific Incident Cases of CDI in Japan (2019–2032)
Table 45: Age-specific Incident Cases of CDI in Japan (2019–2032)
Table 46: Severity-specific Incident Cases of CDI in Japan (2019–2032)
Table 47: Comparison of Marketed Drugs
Table 48: ZINPLAVA (bezlotoxumab), Clinical Trial Description, 2022
Table 49: DIFICID (fidaxomicin), Clinical Trial Description, 2022
Table 50: Comparison of Emerging Therapies Under Development
Table 51: PF-06425090, Clinical Trial Description, 2022
Table 52: VLA84, Clinical Trial Description, 2022
Table 53: GSK2904545A, Clinical Trial Description, 2022
Table 54: Ridinilazole, Clinical Trial Description, 2022
Table 55: MGB-BP-3, Clinical Trial Description, 2022
Table 56: Ibezapolstat, Clinical Trial Description, 2022
Table 57: DAV132, Clinical Trial Description, 2022
Table 58: SYN-004, Clinical Trial Description, 2022
Table 59: DNV3837, Clinical Trial Description, 2022
Table 60: CRS3123, Clinical Trial Description, 2022
Table 61: REBYOTA (RBX2660), Clinical Trial Description, 2022
Table 62: SER-109, Clinical Trial Description, 2022
Table 63: CP101, Clinical Trial Description, 2022
Table 64: NTCD-M3, Clinical Trial Description, 2022
Table 65: VE303, Clinical Trial Description, 2022
Table 66: MBK-01, Clinical Trial Description, 2022
Table 67: LMN-201, Clinical Trial Description, 2022
Table 68: ADS024, Clinical Trial Description, 2022
Table 69: Key Market Forecast Assumptions for PF-06425090
Table 70: Key Market Forecast Assumptions for CP101
Table 71: Key Market Forecast Assumptions for VE303
Table 72: Key Market Forecast Assumptions for NTCD-M3
Table 73: Key Market Forecast Assumptions for REBYOTA (RBX2660)
Table 74: Key Market Forecast Assumptions for SER-109
Table 75: Key Market Forecast Assumptions for MGB-BP-3
Table 76: Key Market Forecast Assumptions for Ridinilazole
Table 77: Market Size of CDI in the 7MM, in USD Million (2019–2032)
Table 78: Market Size of CDI by Therapies in the 7MM, in USD Million (2019–2032)
Table 79: Market Size of CDI in the US, in USD Million (2019–2032)
Table 80: Market Size of CDI by Therapies in the US, in USD Million (2019–2032)
Table 81: Market Size of CDI in the EU-5, in USD Million (2019–2032)
Table 82: Market Size of CDI by Therapies in the EU-5, in USD Million (2019–2032)
Table 83: Market Size of CDI in Germany, in USD Million (2019–2032)
Table 84: Market Size of CDI by Therapies in Germany, in USD Million (2019–2032)
Table 85: Market Size of CDI in France, in USD Million (2019–2032)
Table 86: Market Size of CDI by Therapies in France, in USD Million (2019–2032)
Table 87: Market Size of CDI in Italy, in USD Million (2019–2032)
Table 88: Market Size of CDI by Therapies in Italy, in USD Million (2019–2032)
Table 89: Market Size of CDI in Spain, in USD Million (2019–2032)
Table 90: Market Size of CDI by Therapies in Spain, in USD Million (2019–2032)
Table 91: Market Size of CDI in the UK, in USD Million (2019–2032)
Table 92: Market Size of CDI by Therapies in the UK, in USD Million (2019–2032)
Table 93: Market Size of CDI in Japan, in USD Million (2019–2032)
Table 94: Market Size of CDI by Therapies in Japan, in USD Million (2019–2032)
List of Figures
Figure 1: Symptoms of CDI
Figure 2: Causes of CDI
Figure 3: Risk Factors for CDI
Figure 4: Pathogenesis of CDI
Figure 5: Diagnostic algorithm for confirming CDI
Figure 6: Treatment Algorithm for the Assessment
Figure 7: Total Incident Cases of CDI in the 7MM (2019–2032)
Figure 8: Total Incident Cases of CDI in the US (2019–2032)
Figure 9: Gender-specific Incident Cases of CDI in the US (2019–2032)
Figure 10: Type-specific Incident Cases of CDI in the US (2019–2032)
Figure 11: Age-specific Incident Cases of CDI in the US (2019–2032)
Figure 12: Severity-specific Incident Cases of CDI in the US (2019–2032)
Figure 13: Total Incident Cases of CDI in the EU-5 (2019–2032)
Figure 14: Gender-specific Incident Cases of CDI in the EU-5 (2019–2032)
Figure 15: Type-specific Incident Cases of CDI in the EU-5 (2019–2032)
Figure 16: Age-specific Incident Cases of CDI in the EU-5 (2019–2032)
Figure 17: Severity-specific Incident Cases of CDI in the EU-5 (2019–2032)
Figure 18: Total Incident Cases of CDI in Germany (2019–2032)
Figure 19: Gender-specific Incident Cases of CDI in Germany (2019–2032)
Figure 20: Type-specific Incident Cases of CDI in Germany (2019–2032)
Figure 21: Age-specific Incident Cases of CDI in Germany (2019–2032)
Figure 22: Severity-specific Incident Cases of CDI in Germany (2019–2032)
Figure 23: Total Incident Cases of CDI in France (2019–2032)
Figure 24: Gender-specific Incident Cases of CDI in France (2019–2032)
Figure 25: Type-specific Incident Cases of CDI in France (2019–2032)
Figure 26: Age-specific Incident Cases of CDI in France (2019–2032)
Figure 27: Severity-specific Incident Cases of CDI in France (2019–2032)
Figure 28: Total Incident Cases of CDI in Italy (2019–2032)
Figure 29: Gender-specific Incident Cases of CDI in Italy (2019–2032)
Figure 30: Type-specific Incident Cases of CDI in Italy (2019–2032)
Figure 31: Age-specific Incident Cases of CDI in Italy (2019–2032)
Figure 32: Severity-specific Incident Cases of CDI in Italy (2019–2032)
Figure 33: Total Incident Cases of CDI in Spain (2019–2032)
Figure 34: Gender-specific Incident Cases of CDI in Spain (2019–2032)
Figure 35: Type-specific Incident Cases of CDI in Spain (2019–2032)
Figure 36: Age-specific Incident Cases of CDI in Spain (2019–2032)
Figure 37: Severity-specific Incident Cases of CDI in Spain (2019–2032)
Figure 38: Total Incident Cases of CDI in the UK (2019–2032)
Figure 39: Gender-specific Incident Cases of CDI in the UK (2019–2032)
Figure 40: Type-specific Incident Cases of CDI in the UK (2019–2032)
Figure 41: Age-specific Incident Cases of CDI in the UK (2019–2032)
Figure 42: Severity-specific Incident Cases of CDI in the UK (2019–2032)
Figure 43: Total Incident Cases of CDI in Japan (2019–2032)
Figure 44: Gender-specific Incident Cases of CDI in Japan (2019–2032)
Figure 45: Type-specific Incident Cases of CDI in Japan (2019–2032)
Figure 46: Age-specific Incident Cases of CDI in Japan (2019–2032)
Figure 47: Severity-specific Incident Cases of CDI in Japan (2019–2032)
Figure 48: Patient Journey
Figure 49: Market Size of CDI in the 7MM, in USD Million (2019–2032)
Figure 50: Market Size of CDI by Therapies in the 7MM, in USD Million (2019–2032)
Figure 51: Market Size of CDI in the US, in USD Million (2019–2032)
Figure 52: Market Size of CDI by Therapies in the US, in USD Million (2019–2032)
Figure 53: Market Size of CDI in the EU-5, USD Million (2019–2032)
Figure 54: Market Size of CDI by Therapies in the EU-5, in USD Million (2019–2032)
Figure 55: Market Size of CDI in Germany, USD Million (2019–2032)
Figure 56: Market Size of CDI by Therapies in Germany, in USD Million (2019–2032)
Figure 57: Market Size of CDI in France, USD Million (2019–2032)
Figure 58: Market Size of CDI by Therapies in France, in USD Million (2019–2032)
Figure 59: Market Size of CDI in Italy, USD Million (2019–2032)
Figure 60: Market Size of CDI by Therapies in Italy, in USD Million (2019–2032)
Figure 61: Market Size of CDI in Spain, USD Million (2019–2032)
Figure 62: Market Size of CDI by Therapies in Spain, in USD Million (2019–2032)
Figure 63: Market Size of CDI in the UK, USD Million (2019–2032)
Figure 64: Market Size of CDI by Therapies in the UK, in USD Million (2019–2032)
Figure 65: Market Size of CDI in Japan, USD Million (2019–2032)
Figure 66: Market Size of CDI by Therapies in Japan, in USD Million (2019–2032)
Figure 67: SWOT Analysis
Figure 68: Unmet Needs
Figure 69: Health Technology Assessment
Figure 70: Reimbursement Process in Germany
Figure 71: Reimbursement process in France
Figure 72: Reimbursement process in Italy
Figure 73: Reimbursement process in Spain
Figure 74: Reimbursement process in the United Kingdom
Figure 75: Reimbursement process in Japan
Pfizer
Valneva
GlaxoSmithKline
Summit Therapeutics
MGB Biopharma
Acurx Pharmaceuticals
Da Volterra
Synthetic Biologics
Deinove
Oragenics
C. difficile Monoclonal Antibody
Crestone
MicroPharm Ltd.
SAb Biotherapeutics
Ferring Pharmaceuticals
Seres Therapeutics/Nestlé Health Science
Finch Therapeutics
Destiny Pharma
Vedanta Biosciences
Mikrobiomik Healthcare
Lumen Bioscience
Adiso Therapeutics
Recursion Pharmaceuticals